NCT01399840View on ClinicalTrials.gov

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

May 31, 2014

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Lymphocytic LeukemiaMantle Cell Lymphoma
Interventions
DRUG

BMN 673

Oral capsule with multiple dosage forms given once daily

Trial Locations (7)

46202

Indiana University Simon Cancer Center, Indianapolis

53715

University of Wisconsin, Madison

98109-1023

Seattle Cancer Care Alliance, Seattle

NW1 2BU

University College London, London

SE5 9RS

King's College Hospital, London

M20 4BX

The Christie NHS Foundation, Manchester

NE1 7RU

University of Newcastle Upon Tyne, NHS Foundation Trust, Newcastle upon Tyne

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY